Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPGL008 and SSGJ-706 With or Without Chemotherapy in Advanced NSCLC
NCT07874984Phase 2Not yet recruiting
- Sponsor
- 3SBio
- Start
- Nov 2026
- Primary completion
- Nov 2027
01
Overview
Phase 2, open-label trial of SPGL008 and SSGJ-706 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by 3SBio. Primary endpoints: Incidence of Adverse Events at 24 months and Objective Response Rate at 24 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SPGL008SSGJ-706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07874984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874984.